Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
humoral
immunity
immunomodulation
oncolytic virotherapy
oncolytic viruses
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
05
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include immunosuppression, which may slow the rate of the antiviral antibody response, as well as potentially make the patient more vulnerable to viral infection. Reovirus neutralizing antibody data were aggregated from separate phase I clinical trials of reovirus administered as a single agent or in combination with gemcitabine, docetaxel, carboplatin and paclitaxel doublet or cyclophosphamide. In addition, the kinetics of individual antibody isotypes were profiled in sera collected in these trials. These data demonstrate preserved antiviral antibody responses, with only moderately reduced kinetics with some drugs, most notably gemcitabine. All patients ultimately produced an effective neutralizing antibody response. Patients' responses to infection by reovirus are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.
Sections du résumé
BACKGROUND
Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include immunosuppression, which may slow the rate of the antiviral antibody response, as well as potentially make the patient more vulnerable to viral infection.
METHOD
Reovirus neutralizing antibody data were aggregated from separate phase I clinical trials of reovirus administered as a single agent or in combination with gemcitabine, docetaxel, carboplatin and paclitaxel doublet or cyclophosphamide. In addition, the kinetics of individual antibody isotypes were profiled in sera collected in these trials.
RESULTS
These data demonstrate preserved antiviral antibody responses, with only moderately reduced kinetics with some drugs, most notably gemcitabine. All patients ultimately produced an effective neutralizing antibody response.
CONCLUSION
Patients' responses to infection by reovirus are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.
Identifiants
pubmed: 34301814
pii: jitc-2021-002673
doi: 10.1136/jitc-2021-002673
pmc: PMC8728387
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Front Immunol. 2019 Feb 28;10:332
pubmed: 30873178
Sci Transl Med. 2012 Jun 13;4(138):138ra77
pubmed: 22700953
Clin Cancer Res. 2008 Nov 1;14(21):7127-37
pubmed: 18981012
Invest New Drugs. 2010 Oct;28(5):641-9
pubmed: 19572105
EMBO J. 1998 Jun 15;17(12):3351-62
pubmed: 9628872
Infect Immun. 1972 Dec;6(6):996-1002
pubmed: 4674081
Clin Cancer Res. 2011 Feb 1;17(3):581-8
pubmed: 21106728
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
Clin Cancer Res. 2009 Oct 1;15(19):6158-66
pubmed: 19773377
Gene Ther. 2013 May;20(5):521-8
pubmed: 22895509
Br J Exp Pathol. 1986 Aug;67(4):581-6
pubmed: 3017399
Gene Ther. 2009 May;16(5):689-99
pubmed: 19282847
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Clin Cancer Res. 2020 Jan 1;26(1):71-81
pubmed: 31694832
Mol Ther. 2012 Oct;20(10):1998-2003
pubmed: 22871663
Clin Cancer Res. 2012 Apr 1;18(7):2080-9
pubmed: 22316603
Invest New Drugs. 2013 Jun;31(3):696-706
pubmed: 22886613
Clin Cancer Res. 2008 Jan 1;14(1):259-69
pubmed: 18172278
BMC Cancer. 2011 Jun 06;11:221
pubmed: 21645351
Mol Ther. 2014 Oct;22(10):1851-63
pubmed: 24957982
Int J Cancer. 2014 Mar 1;134(5):1091-101
pubmed: 23982804
J Infect Dis. 2005 Apr 15;191(8):1221-4
pubmed: 15776366
Cancer Res. 2003 Jan 15;63(2):348-53
pubmed: 12543787
Clin Cancer Res. 2015 Mar 15;21(6):1305-12
pubmed: 25424857
Mol Ther. 2015 May;23(5):931-942
pubmed: 25619724
Cancer Immunol Res. 2018 Oct;6(10):1161-1173
pubmed: 30209061
Mol Ther. 2008 Mar;16(3):627-32
pubmed: 18253152
J Infect Dis. 1973 Dec;128(6):811-66
pubmed: 4358125
AIDS. 2016 Oct 23;30(16):2551-2553
pubmed: 27753680
Clin Cancer Res. 2010 Nov 15;16(22):5564-72
pubmed: 20926400
Gene Ther. 2008 Jun;15(12):911-20
pubmed: 18323793
Cell Mol Immunol. 2020 Jun;17(6):561-569
pubmed: 32382130
Clin Cancer Res. 2009 Jan 15;15(2):561-9
pubmed: 19147761
Oncoimmunology. 2017 Mar 3;6(4):e1294296
pubmed: 28507802
Cancer Gene Ther. 2019 Sep;26(9-10):268-281
pubmed: 30467340
Curr Opin Immunol. 2018 Apr;51:83-90
pubmed: 29550660
BMC Cancer. 2012 Aug 24;12:368
pubmed: 22920673
Mol Cancer. 2009 Jul 14;8:47
pubmed: 19594950